2909 T3D2867 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. [PubChem] 41372-20-7 6005 C17H17NO2 267.125930 White powder. 1.66E+004 mg/L 100% following subcutaneous administration The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the brain. Apomorphine has been shown to improve motor function in an animal model of Parkinson's disease. In particular, apomorphine attenuates the motor deficits induced by lesions in the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in primates. Hepatic Half Life: 40 minutes (range 30 - 60 minutes) LD50: 0.6 mmoles/kg (Intraperitoneal, Mouse) (A308) No indication of carcinogenicity to humans (not listed by IARC). For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease. 2009-07-21T20:27:28Z 2014-12-24T20:25:52Z Apomorphine 48538 Apomorphine DB00714 true [H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23 C17H17NO2 InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1 InChIKey=VMWNQDUVQKEIOC-CYBMUJFWSA-N 267.3224 267.125928793 Exogenous Solid 3.1 HMDB14852 CHEMBL53 5783 <p>Narayanasamy Gurusamy, &#8220;Process for Making Apomorphine and Apocodeine.&#8221; U.S. Patent US20100228032, issued September 09, 2010.</p>